PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 35236826-8 2022 Importantly, MUC15/c-MET/PI3K/AKT/SOX2 axis determines the responses of hepatoma cells to lenvatinib treatment, and MUC15 overexpression abrogated lenvatinib resistance. lenvatinib 90-100 AKT serine/threonine kinase 1 Homo sapiens 30-33 35489726-0 2022 Inactivation of AKT/ERK Signaling and Induction of Apoptosis Are Associated With Amentoflavone Sensitization of Hepatocellular Carcinoma to Lenvatinib. lenvatinib 140-150 AKT serine/threonine kinase 1 Homo sapiens 16-19 35489726-7 2022 RESULTS: We found that amentoflavone enhances the suppressive effect of AKT/ERK signaling induced by lenvatinib and, thus, sensitizes HCC to lenvatinib. lenvatinib 101-111 AKT serine/threonine kinase 1 Homo sapiens 72-75 35489726-7 2022 RESULTS: We found that amentoflavone enhances the suppressive effect of AKT/ERK signaling induced by lenvatinib and, thus, sensitizes HCC to lenvatinib. lenvatinib 141-151 AKT serine/threonine kinase 1 Homo sapiens 72-75 35489726-9 2022 CONCLUSION: Amentoflavone sensitization of HCC to lenvatinib is associated with AKT/ERK inactivation and apoptosis induction. lenvatinib 50-60 AKT serine/threonine kinase 1 Homo sapiens 80-83 35238496-6 2022 Mechanistically, ITGB8 regulated lenvatinib resistance through an HSP90-mediated stabilization of AKT and enhanced AKT signaling. lenvatinib 33-43 AKT serine/threonine kinase 1 Homo sapiens 98-101 35238496-6 2022 Mechanistically, ITGB8 regulated lenvatinib resistance through an HSP90-mediated stabilization of AKT and enhanced AKT signaling. lenvatinib 33-43 AKT serine/threonine kinase 1 Homo sapiens 115-118 35238496-7 2022 In support of this model, either an AKT inhibitor MK-2206 or an HSP90 inhibitor 17-AAG resensitized LR HCC cells to lenvatinib treatment. lenvatinib 116-126 AKT serine/threonine kinase 1 Homo sapiens 36-39 35238496-8 2022 Conclusion: Collectively, our results establish a crucial role of ITGB8 in lenvatinib resistance, and suggest that targeting the ITGB8/HSP90/AKT axis is a promising therapeutic strategy in patients with HCC exhibiting lenvatinib resistance. lenvatinib 218-228 AKT serine/threonine kinase 1 Homo sapiens 141-144 35236826-8 2022 Importantly, MUC15/c-MET/PI3K/AKT/SOX2 axis determines the responses of hepatoma cells to lenvatinib treatment, and MUC15 overexpression abrogated lenvatinib resistance. lenvatinib 147-157 AKT serine/threonine kinase 1 Homo sapiens 30-33 33995632-0 2021 Lenvatinib induces anticancer activity in gallbladder cancer by targeting AKT. lenvatinib 0-10 AKT serine/threonine kinase 1 Homo sapiens 74-77 35252056-12 2022 MiR-128-3p and c-Met participate in the mechanisms underlying lenvatinib resistance through regulating Akt that mediates the apoptotic pathway and ERK (extracellular-signal-regulated kinase) modulating cell cycle progression. lenvatinib 62-72 AKT serine/threonine kinase 1 Homo sapiens 103-106 33995632-9 2021 Treatment with lenvatinib decreased the expression of MMP-2, CEMIP, CDK2, CDK4 and cyclin D1, and increased the expression of cleaved caspase-9, which was mediated by the inactivation of the PI3K/AKT pathway in vitro. lenvatinib 15-25 AKT serine/threonine kinase 1 Homo sapiens 196-199 33995632-11 2021 Besides, Lenvatinib suppressed GBC cell growth in vivo by targeting p-AKT. lenvatinib 9-19 AKT serine/threonine kinase 1 Homo sapiens 70-73 33670725-5 2021 We found that the combination of lenvatinib with MEK inhibitors enhanced the antitumor effects of monotherapy with either agent in vitro and in vivo, and these effects may be through the AKT (Protein Kinase B) and extracellular signal-regulated kinase (ERK) signaling pathways. lenvatinib 33-43 AKT serine/threonine kinase 1 Homo sapiens 187-190 33609067-5 2021 Lenvatinib restrained proliferation and promoted apoptosis of LX-2 with suppressed phosphorylation of extracellular signal-regulated kinase 1/2 and AKT. lenvatinib 0-10 AKT serine/threonine kinase 1 Homo sapiens 148-151 33419805-9 2021 CONCLUSION: Altogether, lenvatinib induced extrinsic/intrinsic apoptosis and suppressed migration/invasion ability of NSCLC cells that was associated with AKT/NF-kappaB signaling inactivation. lenvatinib 24-34 AKT serine/threonine kinase 1 Homo sapiens 155-158 29517103-7 2018 In addition, lenvatinib inhibited EGFR, AKT and ERK1/2 phosphorylation and downregulated cyclin D1 in the ATC cells. lenvatinib 13-23 AKT serine/threonine kinase 1 Homo sapiens 40-43 33419805-0 2021 Lenvatinib Inhibits AKT/NF-kappaB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer. lenvatinib 0-10 AKT serine/threonine kinase 1 Homo sapiens 20-23 33419805-4 2021 However, whether lenvatinib may affect AKT/NF-kappaB in NSCLC remains unknown. lenvatinib 17-27 AKT serine/threonine kinase 1 Homo sapiens 39-42 33148422-9 2021 KEY FINDINGS: Here, we revealed that overexpressed FGFR1 and its downstream AKT/mTOR and ERK signaling activation could induce lenvatinib resistance in HCC. lenvatinib 127-137 AKT serine/threonine kinase 1 Homo sapiens 76-79 33148422-12 2021 Mechanism studies revealed that Oxysophocarpine downregulated FGFR1 expression along with downstream AKT/mTOR and ERK signaling to sensitize lenvatinib against FGFR1-overexpressed HCC. lenvatinib 141-151 AKT serine/threonine kinase 1 Homo sapiens 101-104 31853327-0 2020 Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways. lenvatinib 18-28 AKT serine/threonine kinase 1 Homo sapiens 108-111